Last reviewed · How we verify
TG103
TG103 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.
At a glance
| Generic name | TG103 |
|---|---|
| Also known as | Administered SC |
| Sponsor | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TG103 is an investigational small-molecule tyrosine kinase inhibitor in Phase 3 development by CSPC Baike. While the precise molecular targets have not been widely disclosed in public literature, it is being evaluated for potential anti-cancer activity. The drug is under clinical development but detailed mechanistic and efficacy data remain limited in the public domain.
Approved indications
Common side effects
Key clinical trials
- A Study of TG103 Injection in Non-diabetic Overweight or Obesity (PHASE3)
- A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus (PHASE3)
- A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus (PHASE3)
- A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity (PHASE2)
- A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes (PHASE1)
- A Study of TG103 Injection in Type 2 Diabetes Subjects (PHASE2)
- A Study of TG103 Injection in Overweight or Obesity (PHASE2)
- A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TG103 CI brief — competitive landscape report
- TG103 updates RSS · CI watch RSS
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. portfolio CI